Concepedia

Trevor McMullan

TM

Statistics

Publications

8

Citations

606

H-Index

8

Active since

2019

Affiliations

Inovio Pharmaceuticals (United States)(Current)

The Wistar Institute

Hospital of the University of Pennsylvania

University of Pennsylvania

The Barbara Ann Karmanos Cancer Institute

Trevor McMullan is an author at Inovio Pharmaceuticals (United States) specializing in t cell immunity, immunology, and medicine.

Top concepts

Publications per year

2019–2022

8

Publications

8

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Pablo Tebas, ShuPing Yang, Jean Boyer et al. · EClinicalMedicine · 2020 · 276 citations · Full text

Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers

Pablo Tebas, Kimberly A. Kraynyak, Ami Patel et al. · The Journal of Infectious Diseases · 2019 · 119 citations

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

Kimberly A. Kraynyak, Elliott Blackwood, Joseph Agnes et al. · The Journal of Infectious Diseases · 2022 · 59 citations · Full text

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants

Viviane M. Andrade, Aaron Christensen-Quick, Joseph Agnes et al. · npj Vaccines · 2021 · 48 citations · Full text

Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors

Robert H. Vonderheide, Kimberly A. Kraynyak, Anthony F. Shields et al. · Journal for ImmunoTherapy of Cancer · 2021 · 42 citations · Full text

1–5 of 8